Surgery Partners Company Insiders
SGRY Stock | USD 29.83 0.11 0.37% |
Surgery Partners' insiders are aggressively selling. The analysis of insiders' sentiment of trading Surgery Partners stock suggests that vertually all insiders are panicking at this time. Surgery Partners employs about 10.5 K people. The company is managed by 34 executives with a total tenure of roughly 173 years, averaging almost 5.0 years of service per executive, having 308.82 employees per reported executive.
Michael Doyle CEO CEO, Director |
Clifford Adlerz CEO Interim CEO, Director |
Surgery Partners' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-03-13 | Jason Eric Evans | Disposed 4840 @ 29.71 | View | ||
2024-03-11 | Jason Eric Evans | Disposed 1984 @ 29.44 | View | ||
2024-02-12 | Jason Eric Evans | Disposed 5780 @ 35.08 | View | ||
2024-02-06 | Danielle Burkhalter | Disposed 167 @ 32.24 | View | ||
2024-02-02 | Marissa Brittenham | Disposed 1637 @ 31.89 | View | ||
2023-12-19 | Wayne S Deveydt | Disposed 168130 @ 33.44 | View | ||
2023-09-05 | Harrison R Bane | Disposed 3835 @ 35.98 | View | ||
2023-08-29 | David T Doherty | Disposed 202 @ 35.21 | View | ||
2023-06-29 | Jason Eric Evans | Disposed 1892 @ 45.1 | View | ||
2023-05-17 | Bradley R Owens | Disposed 7191 @ 36.31 | View | ||
2023-03-31 | Jason Eric Evans | Disposed 7674 @ 34.26 | View |
Monitoring Surgery Partners' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Surgery |
Surgery Partners' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Surgery Partners' future performance. Based on our forecasts, it is anticipated that Surgery will maintain a workforce of slightly above 10500 employees by April 2024.Surgery Partners Management Team Effectiveness
The company has return on total asset (ROA) of 0.0383 % which means that it generated a profit of $0.0383 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0407 %, meaning that it created $0.0407 on every $100 dollars invested by stockholders. Surgery Partners' management efficiency ratios could be used to measure how well Surgery Partners manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.07 in 2024, whereas Return On Assets are likely to drop (0) in 2024. At this time, Surgery Partners' Non Currrent Assets Other are fairly stable compared to the past year. Asset Turnover is likely to rise to 0.43 in 2024, whereas Total Assets are likely to drop slightly above 4.6 B in 2024.Common Stock Shares Outstanding is likely to rise to about 131.9 M in 2024, whereas Net Loss is likely to drop (51.6 M) in 2024.
Surgery Partners Workforce Comparison
Surgery Partners is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 48,196. Surgery Partners totals roughly 10,500 in number of employees claiming about 22% of equities under Health Care industry.
Surgery Partners Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Surgery Partners insiders, such as employees or executives, is commonly permitted as long as it does not rely on Surgery Partners' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Surgery Partners insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 0.4 | 12 | 30 | 151,052 | 53,383 |
2023-12-01 | 0.0769 | 1 | 13 | 100,000 | 33,512,743 |
2023-03-01 | 0.4286 | 15 | 35 | 277,401 | 125,093 |
2022-12-01 | 5.0 | 5 | 1 | 27,581,019 | 4,338 |
2022-06-01 | 0.5556 | 5 | 9 | 20,150 | 129,414 |
2022-03-01 | 0.4706 | 16 | 34 | 178,753 | 194,009 |
2021-09-01 | 0.5 | 1 | 2 | 2,000 | 184.00 |
2021-06-01 | 0.1667 | 2 | 12 | 45,217,850 | 814,279 |
2021-03-01 | 1.069 | 31 | 29 | 404,758 | 94,583 |
2020-12-01 | 0.1111 | 1 | 9 | 4,199 | 16,274 |
2020-03-01 | 2.75 | 11 | 4 | 503,785 | 11,915 |
2019-09-01 | 1.0 | 3 | 3 | 51,000 | 115,423 |
2019-06-01 | 3.0 | 6 | 2 | 647,923 | 9,063 |
2019-03-01 | 1.2778 | 23 | 18 | 1,962,079 | 29,616 |
2018-12-01 | 1.0 | 5 | 5 | 208,169 | 201,991 |
2018-09-01 | 2.0 | 4 | 2 | 31,460 | 19,789 |
2018-06-01 | 0.25 | 1 | 4 | 14,749 | 0.00 |
2018-03-01 | 2.0 | 8 | 4 | 882,077 | 3,621 |
2017-12-01 | 0.25 | 1 | 4 | 67,264 | 2,846 |
2017-03-01 | 2.0 | 10 | 5 | 117,433 | 11,580 |
2016-09-01 | 2.0 | 2 | 1 | 22,024 | 2,500 |
2015-12-01 | 0.3333 | 1 | 3 | 4,015 | 1,477,430 |
2015-09-01 | 0.1667 | 1 | 6 | 4,473 | 0.00 |
Surgery Partners Notable Stakeholders
A Surgery Partners stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Surgery Partners often face trade-offs trying to please all of them. Surgery Partners' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Surgery Partners' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael Doyle | CEO, Director | Profile | |
Clifford Adlerz | Interim CEO, Director | Profile | |
Christopher Laitala | Independent Chairman of the Board | Profile | |
Wayne DeVeydt | Executive Chairman | Profile | |
Bradley Owens | President Group | Profile | |
Bryan Fisher | COO, Executive Vice President | Profile | |
Harrison Bane | President Group | Profile | |
Jennifer Baldock | Senior Vice President General Counsel, Secretary | Profile | |
Teresa Sparks | CFO, Executive Vice President | Profile | |
Carollee Brinkman | President - National Group | Profile | |
George Goodwin | President - American Group | Profile | |
Dennis Dean | Senior Vice President Corporate Controller | Profile | |
Brandan Lingle | Group President of Ancillary Services | Profile | |
John Crysel | Group President of Surgery Partners’ National Group | Profile | |
Eric Evans | COO, Executive Vice President | Profile | |
Anthony Taparo | President - Atlantic Group | Profile | |
Ronald Zelhof | Senior Vice President - Operation | Profile | |
David Doherty | Executive CFO | Profile | |
Thomas Cowhey | CFO, Principal Accounting Officer | Profile | |
David Kretschmer | Chief Strategy and Transformation Officer and interim CFO | Profile | |
Adam Feinstein | Independent Director | Profile | |
Teresa DeLuca | Director | Profile | |
Andrew Kaplan | Director | Profile | |
Christopher Gordon | Director | Profile | |
Brent Turner | Director | Profile | |
Matthew Lozow | Independent Director | Profile | |
John Deane | Independent Director | Profile | |
Devin OReilly | Director | Profile | |
Neil Zieselman | Senior Controller | Profile | |
Varun Gadhok | Senior Officer | Profile | |
Angela Justice | Chief Human Resource Officer | Profile | |
Danielle Burkhalter | Chief Officer | Profile | |
Roxanne Womack | Senior Officer | Profile | |
Marissa Brittenham | Ex Officer | Profile |
About Surgery Partners Management Performance
The success or failure of an entity such as Surgery Partners often depends on how effective the management is. Surgery Partners management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Surgery management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Surgery management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for 2024 | ||
Return On Capital Employed | 0.06 | 0.07 | |
Return On Assets | (0) | (0) | |
Return On Equity | (0.01) | (0.01) |
The data published in Surgery Partners' official financial statements usually reflect Surgery Partners' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Surgery Partners. For example, before you start analyzing numbers published by Surgery accountants, it's critical to develop an understanding of what Surgery Partners' liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Surgery Partners' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Surgery Partners' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Surgery Partners' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Surgery Partners. Please utilize our Beneish M Score to check the likelihood of Surgery Partners' management manipulating its earnings.
Surgery Partners Workforce Analysis
Traditionally, organizations such as Surgery Partners use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Surgery Partners within its industry.Surgery Partners Manpower Efficiency
Return on Surgery Partners Manpower
Revenue Per Employee | 261.3K | |
Revenue Per Executive | 80.7M | |
Net Loss Per Employee | 1.1K | |
Net Loss Per Executive | 350K | |
Working Capital Per Employee | 35.4K | |
Working Capital Per Executive | 10.9M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Surgery Partners. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Surgery Stock please use our How to Invest in Surgery Partners guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Surgery Stock analysis
When running Surgery Partners' price analysis, check to measure Surgery Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Surgery Partners is operating at the current time. Most of Surgery Partners' value examination focuses on studying past and present price action to predict the probability of Surgery Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Surgery Partners' price. Additionally, you may evaluate how the addition of Surgery Partners to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Surgery Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Surgery Partners. If investors know Surgery will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Surgery Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.09) | Revenue Per Share 21.839 | Quarterly Revenue Growth 0.04 | Return On Assets 0.0383 | Return On Equity 0.0407 |
The market value of Surgery Partners is measured differently than its book value, which is the value of Surgery that is recorded on the company's balance sheet. Investors also form their own opinion of Surgery Partners' value that differs from its market value or its book value, called intrinsic value, which is Surgery Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Surgery Partners' market value can be influenced by many factors that don't directly affect Surgery Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Surgery Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Surgery Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Surgery Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.